Artiva Biotherapeutics Inc. ARTV

$11.77 -0.23 (-1.92%)

Valuation

Market cap
—
Revenue TTM
$33,492,000
Net income TTM
$-27,696,000
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
342,500
Avg volume
—
Day's range
$11.71 – $12.26
Shares out
—
Stochastic %K
—
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,...

Show more

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 267 4467
Website
https://www.artivabio.com
Address
5505 Morehouse Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

YouVSYou Sep 28, 1:15 PM
$ARTV $OCUL Ww this week $SCYX @BOUDIN420 aleeted the team Friday before the Chase $NVDA but back into res 230.77/228.85 $SOAR .34/.45
0 replies
Goodstockday Sep 24, 2:40 PM
$ARTV Treatment results sound encouraging. CEO said they can get COGS to 8K per treatment. Treatment expected to last 1yr minimum. How can this compete with off the shelf CAR-T? For example, $FATE cost per treatment is 3K and can go much lower with volume. They will likely eventually have a treatment with no chemo. A little further behind is In-vivo CAR-T. I just don’t see a long term future for the $ARTV approach. Am I missing something?
1 replies
aletz Sep 23, 9:12 PM
$ARTV https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Announces-Oral-Presentation-of-AlloNK-Clinical-Data-at-the-17th-International-Symposium-on-Sjgrens-Disease/default.aspx
0 replies
Papermoon347 Sep 21, 4:22 PM
$ARTV Bullshit
0 replies
Merlintrader Sep 19, 5:53 PM
Artiva Biotherapeutics ($ARTV) Stock Hub Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies
aletz Sep 15, 3:39 PM
$ARTV $9.06 added more, thank you
0 replies
theBigDollarski Sep 15, 2:43 PM
$ARTV I'm in at 9.43....thanks for the Dip
0 replies
Merlintrader Sep 13, 10:11 PM
$ARTV — Artiva shareholders approve equity-plan expansion Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies